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ABSTRACT One hundred thirty-eight new Epstein-Barr virus (EBV) genome se-
quences have been determined. One hundred twenty-five of these and 116 from
previous reports were combined to produce a multiple-sequence alignment of 241
EBV genomes, which we have used to analyze variation within the viral genome.
The type 1/type 2 classification of EBV remains the major form of variation and is
defined mostly by EBNA2 and EBNA3, but the type 2 single-nucleotide polymor-
phisms (SNPs) at the EBNA3 locus extend into the adjacent gp350 and gp42 genes,
whose products mediate infection of B cells by EBV. A small insertion within the
BART microRNA region of the genome was present in 21 EBV strains. EBV from saliva
of U.S. patients with chronic active EBV infection aligned with the wild-type EBV ge-
nome with no evidence of WZhet rearrangements. The V3 polymorphism in the Zp
promoter for BZLF1 was found to be frequent in nasopharyngeal carcinoma cases
from both Hong Kong and Indonesia. Codon usage was found to differ between la-
tent and lytic cycle EBV genes, and the main forms of variation of the EBNA1 protein
have been identified.
IMPORTANCE Epstein-Barr virus causes most cases of infectious mononucleosis and
posttransplant lymphoproliferative disease. It contributes to several types of cancer,
including Hodgkin’s lymphoma, Burkitt’s lymphoma, diffuse large B cell lymphoma,
nasopharyngeal carcinoma, and gastric carcinoma. EBV genome variation is impor-
tant because some of the diseases associated with EBV have very different inci-
dences in different populations and geographic regions, and differences in the EBV
genome might contribute to these diseases. Some specific EBV genome alterations
that appear to be significant in EBV-associated cancers are already known, and cur-
rent efforts to make an EBV vaccine and antiviral drugs should also take account of
sequence differences in the proteins used as targets.
KEYWORDS Epstein-Barr virus
Most of the world’s population is thought to be infected by Epstein-Barr virus (EBV)without any symptoms or disease. However, some people suffer from infectious
mononucleosis after primary infection, and EBV is also present in the malignant cells of
several types of cancer, where it appears to contribute to the pathogenesis of the
disease (1). Some of the EBV-associated diseases differ significantly in incidence in
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different parts of the world, raising the possibility that variation in the genome of EBV
is relevant to some of these diseases.
There is already some evidence for mutations in EBV being linked to certain types
of cancer. For example, about 10% of African Burkitt’s lymphoma (BL) cases contain EBV
with a deletion of the EBNA2 locus, which has been proposed to result in a higher
expression of the EBV BHRF1 homologue of the antiapoptosis BCL2 protein (2). Also,
mutations in the EBNA3B gene have been shown to make EBV more oncogenic, causing
disease similar to diffuse large B cell lymphoma (DLBCL) in a mouse model system, and
examples of mutated EBNA3B have been found in human EBV-associated DLBCL cases
(3). However, identifying EBV mutations in cancers requires a detailed understanding of
the background variation in the normal viral genome so that potentially significant
mutations can be distinguished from natural variation in the virus genome.
Variation in the viral genome is also relevant to development of potential vaccines
for EBV, where strain differences have already been identified in the relevant part of the
gp350 protein (4), which is a key component of current vaccines.
In recent reports we analyzed variation in some key genes of EBV using a combi-
nation of templated and de novo-assembled viral genomes (4, 5). Here, we present the
new de novo-assembled genome sequences of 138 EBV strains and use these genomes
and previously published sequences to identify major patterns of variation. We explore
single-nucleotide polymorphisms (SNPs) which have been proposed to be related to
EBV-associated diseases, infections with multiple EBV strains, examples of genetic
linkage within the EBV genome, and differences in codon usage between latent and
lytic cycle genes.
RESULTS
One hundred thirty-eight new EBV genome sequences and a multiple-
sequence alignment of 241 EBV genomes. Here, we report new de novo assemblies
of 138 EBV genome sequences. A total of 125 of these and 116 previously published de
novo-assembled EBV genomes were used to create a multiple-sequence alignment
(MSA) of 241 EBV genomes. We used this to analyze major patterns of variation in the
virus genome. Table S1 in the supplemental material lists all of the EBV genome
sequences used in this paper, with accession numbers and details of the samples from
which they were derived. In addition to the 241 aligned EBV genomes, Table S1
includes a small number of additional EBV genome sequences that were omitted from
the MSA either because they were essentially duplicates or because they contain
rearrangements which would gap the MSA excessively.
The 241 sequences that are analyzed below include 130 that were determined
directly from primary material (38 from saliva and 92 from other primary biopsy
specimens). Samples came from many different geographic regions of the world; this
information is listed in Table S1, and the geographic origin of the sample is represented
by colors in the figures where relevant.
Major patterns of variation are type1/type 2 and geographic. Our previous
principal component analysis (PCA) of 84 EBV genomes (5) found that type 1/type 2 was
the major form of variation and showed that EBNA2 and EBNA3 genes accounted for
most of the difference between type 1 and type 2 sequences. Type 1/type 2 remains the
largest type of systematic variation in the enlarged set of 241 sequences, which clearly
cluster into 2 groups (Fig. 1A) in the first 3 components of the PCA (which account for
45% of the variation in this set of sequences). Comparison of consensus sequences of
the type 1 and type 2 genomes with this enlarged data set again showed that SNPs in
the regions of EBNA2 and EBNA3 genes are the main differences between type 1 and
type 2 (Fig. 1C).
Some features of the PCA procedure used here differ from our previous approach
(5). As before, SNPs are determined relative to a consensus of all the sequences, which
in practice is close to a consensus of the type 1 sequences because of the smaller
number of type 2 genomes analyzed. However, most PCA procedures measure SNPs
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only in those nucleotide positions which are A, C, T, G, or N in the MSA, ignoring
nucleotide positions where there is a deletion in one of the sequences. This tends to
reduce the number of positions sampled in MSAs that contain many sequences and
might overlook insertions or deletions characteristic of groups of strains. In this new
FIG 1 (A) PCA of 241 EBV genomes from the multiple-sequence alignment shown in a three-dimensional plot of PCA1, PCA2, and PCA3.
Each genome is represented by a colored dot (geographic color codes are shown in panel B). The cluster of type 2 strains is circled. (B)
Plot of PCA1 against PCA2 for the 217 type 1 strains, with each genome sequence represented by a colored dot. The Asian and Indonesian
strains cluster away from African and European strains. (C) SNPs of a type 2 consensus genome relative to the type 1 consensus are plotted
as number of SNPs in a 500-nt window along the EBV genome (numbered as in the MSA). The positions of EBNA2, BPLF1, gp350, EBNA3,
gp42, and LMP1 coding sequences are marked. The peak marked by the asterisk is in the same location as the insertion shown in Fig. 1D.
(D) Position of the insertion of 71 to 73 nt in 21 strains in the MSA of 241 EBV genome sequences on a scale numbered as in the
NC_007605 reference sequence. The positions of Mir BART 21 and 18 are shown.
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analysis we have modified the PCA to include positions with inserted or deleted
nucleotides. To simplify the analysis we have only scored SNPs at positions where more
than 5 of the 241 sequences differ from the consensus, taking the view that less
frequent SNPs would not affect the results significantly and are unlikely to be biolog-
ically significant. Consequently, SNPs at 10,819 positions within the MSA of EBV
genomes contributed to the PCA.
Within the type 1 sequences, the first two components of the PCA tended to
separate, for example, the Asian (China, Hong Kong, Taiwan, and Japan) (blue), Indo-
nesian (light blue), and Papua New Guinean (brown) strains from the rest (Fig. 1B). For
each geographic group there were a few outliers which could now be excluded from
the identification of groups of closely related sequences, which we consider here to be
characteristic of a geographic region. A phylogenetic tree (Fig. S1) of preliminary
templated assemblies (4) of 233 EBV whole-genome sequences (mostly the same
strains as those in the MSA of 241 de novo-assembled sequences) also helped in this
selection process. The EBV sequences which were chosen to represent each geographic
group are listed in Table S1. These sequences were used to derive a consensus for each
geographic group. Comparison of the consensus sequence for each chosen geographic
group and the consensus of all the type 1 sequences did not reveal simple groups of
SNPs that were uniquely definitive of each geographic group; instead, a complex
mosaic of SNPs determines the geographic differences. Detailed analysis of this will be
published elsewhere, but one prominent feature was an insertion of 71 to 73 nucleo-
tides (nt) in a subset of the sequences in the BART region between mIR BART 21 and
mIR BART 18 (Fig. 1D). Twenty-one EBV genomes in the MSA contained this insertion
(Table S1), and these included several from Papua New Guinea and some type 2 EBV
genomes, including AG876, the reference type 2 genome. The small peak marked with
an asterisk in Fig. 1C showing SNPs that distinguish EBV type 2 from type 1 corresponds
to this location.
Genetic linkage in the EBV genome. In contrast to most of the EBV genome, where
variation is relatively low, the reference type 1 and type 2 EBNA2 have identical
nucleotides at only 51% of the coding sequence, and the reference EBNA3 loci are only
identical at 72% of their sequences. The relatively large differences in sequence
between the type 1 and type 2 versions of EBNA2 and the EBNA3 genes are considered
to prevent homologous recombination between the types at these points and are thus
thought to allow the persistence of the alleles in the viral population (6). Although they
are separated by over 40 kb of EBV genome on either side in the EBV episome in which
extensive historic recombination is generally observed (5), there is strong genetic linkage of
the EBNA2 and EBNA3 genes within the types. In the enlarged set of 241 EBV genomes
analyzed here, 217 have type 1 EBNA2 and EBNA3, and 22 have type 2 EBNA2 and EBNA3.
Only 2 isolates have type 1 EBNA2 with type 2 EBNA3s, and there are no genomes with type
2 and type 1 EBNA2. Therefore, 99% of the EBV genomes show type-specific linkage of
EBNA2 and EBNA3 (linkage significant with a P value of 0.0001).
The type-specific sequence at the EBNA3 locus does not stop precisely at the
boundaries of the EBNA3 genes, and we reported previously (4) how its effect could be
observed in the N terminus of the adjacent gp350 gene (BLLF1), whose protein product
mediates EBV infection by binding to CD21 on the B cell. Certain SNPs (including the
V3 SNP) in the Zp promoter, which initiates the switch between latency and the viral
lytic cycle, were also found to be linked to the type 1/type 2 difference (4). Within this
zone of the genome, the gene immediately on the right-hand side of the EBNA3 region
on the EBV genome map is the gp42 glycoprotein gene. The gp42 protein also partly
mediates B cell infection by EBV through its binding to major histocompatibility
complex class II. A phylogenetic tree of gp42 DNA sequences (Fig. S2) clearly segregates
the type 2 strains. At the amino acid level, the key differences from type 1 gp42 are
A38S, Q92K, G113E, and C114R (Fig. 2). These amino acids are not known to be contact
residues of type 1 gp42 with gH or HLA-DR1 (7) but might affect folding or other
interactions and be relevant to infection efficiency by type 2 EBV. The sequence
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differences are also potentially significant for EBV vaccines that may include gp42 as an
immunogen (8).
We previously classified variation in the C-terminal DNA binding domain of EBNA1
into two main groups, determined by variation in 5 amino acids distributed in the
sequence; these are PSMVT in the reference strain or QCIGP in many other strains (4).
These groups also correlated with variation at amino acid 487, which can be either V,
A, L, or T (4). PSMVT strains have V or A at 487, whereas QCIGP strains have L or T at
487 (4). We have now extended that analysis by identifying major patterns of poly-
morphism in the N-terminal part of EBNA1 and integrating those results with the
C-terminal variation (Fig. 3). Even though its protein sequence is divided into two
domains by the Gly-Ala repeat sequence (about 229 amino acids in length in B95-8
EBV), there is linkage in variation of the N- and C-terminal domains of EBNA1. To
understand the distribution of variation, N-terminal domain amino acids 14 to 87 and
C-terminal amino acids 445 to 614 (which contained the relevant polymorphisms) were
concatenated, and a resulting phylogenetic tree was labeled with the same color
scheme as that used before (4) (Fig. S3). Figure 3A shows the positions of the N-terminal
variant amino acids (QEA, T20S, and E24DG27S) in relation to the previously described
C-terminal 487 polymorphisms and the 585 I variant. In Fig. 3B, QEA (E16Q, G18E, T85A)
is shown to be linked to 487 T and V but not 487 A and L (and thereby not linked to
the PSMVT/QCIGP haplotypes). In addition, T20S is linked to 487 V, whereas
E24DG27S is linked to 487 T (detailed data are shown in Fig. S3). The QE part of this
N-terminal variation has been noted previously (9) but not these larger patterns of
linkage. The T585I C-terminal variation is linked to 487V and is at the same amino acid
position as the T of PSMVT. When the functional significance of these polymorphisms
is explored experimentally, this understanding of the relationship of N- and C-terminal
variation of EBNA1 will help focus analysis of EBNA1 polymorphism on combinations
which are present in natural isolates of EBV. There is still no linkage between the type
1/type 2 classification and variation in EBNA1 (Fig. S3).
SNPs reported to be linked to NPC. The SNP G155391A in the RPMS1 open reading
frame has been correlated with the high incidence of nasopharyngeal carcinoma (NPC)
in southern China (10). Comparison of EBV sequences from North and South China
identified this SNP; the consequent Asp-to-Asn amino acid change in the RPMS1
protein was found to reduce the stability of the protein (10), although uncertainty
remains about whether the RPMS1 protein is expressed in EBV-infected cells (11). A
further sequence study supported this distribution of the SNP selectively in southern
China (12). In our data, 95% of NPC samples from China and Hong Kong had this
G155391A SNP (Fig. 4A; detailed data are shown in Fig. S4, sheet 1). However, there is
FIG 2 Linkage of gp42 protein sequence variation at the indicated amino acids relative to type 1 or type
2 EBNA3, comparing 24 type 2 EBNA3 protein sequences with 212 type 1 EBNA3 protein sequences.
Detailed values and the phylogenetic tree are shown in Fig. S2. Significant differences were determined
with an analysis of variance (ANOVA) test. **, P  0.005.
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also an elevated frequency of NPC in Indonesia, but only 1 of our 20 Indonesian NPC
cases had the G155391A SNP (5%) (Fig. 4A). Our results therefore support the high
frequency of the G155391A SNP in EBV sequences from Hong Kong and southern China
but question the more general relationship to NPC, since G155391A is only rarely
present in NPC cases from Indonesia.
A more frequent SNP in the adjacent codon of the RPMS1 open reading frame
occurs at C155389T and changes the RPMS1 amino acid Pro to Leu. Seventy of 237
isolates (29.5%) have this SNP (Fig. S4, sheet 1), which was relatively frequent in EBV
from Indonesia and Papua New Guinea but could also be found in EBV from other
geographic regions. There was no relationship of this SNP to disease in our data set.
Similarly, for EBER2 a polymorphism (named Ch; the prototype is designated P) has
been reported that was linked to southern Chinese NPC strains (13). This region of
EBER2 has the sequence GcTgtgcggtgctGccgTc in Ch isolates but is TcAgtgcggtgctAc
cgAc in the P strains (Fig. S4, sheet 2, lists strains classified by this polymorphism).
Again, this polymorphism is frequent in southern Chinese NPC strains but has a much
lower incidence in Indonesian NPC isolates (Fig. 4A), questioning its relationship to NPC.
Several previous studies have noted the V3 polymorphism in the Zp promoter (4, 14,
15, 16), and recent work has shown that this affects Zp function, the V3 form inducing
BZLF1 expression, and the lytic cycle of EBV in lymphocytes more strongly (17). The V3
form of Zp was found to be enriched in the EBV present in African BL (17). The Zp V3
allele has also been shown to be overrepresented in NPC cases from Hong Kong
containing type 1 EBV (18). This was confirmed in our data for Hong Kong, China, and
Taiwan, which show a higher frequency of Zp V3 in the NPC cases than normal isolates
in our study (Fig. 4B; detailed data are shown in Fig. S4, sheet 3). A high frequency of
V3 was also present in the NPC cases from Indonesia compared to normal infections
from other parts of the world (Fig. 4B). Although the percentage of V3 in NPC cases was
FIG 3 (A) Schematic illustration of locations of the main EBNA1 variant amino acids under a scale of
amino acid numbers of B95-8 EBNA1. The Gly-Ala region is marked, and the regions of nt 14 to 87
and 445 to 614, which were concatenated to make the phylogenetic tree (Fig. S3), are shown. (B)
Numbers of strains (out of 260) with either the QEA, T20S, E24DG2S, or T585I variant plotted in
relation to amino acid 487 V, A, L, or T. In these EBNA1 sequences, 487 L or T is always found with
the QCIGP haplotype. Significant differences were determined with an ANOVA test. **, P  0.005. Full
details are shown in Fig. S3.
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also higher than that in normal infections from Indonesia (Fig. 4B), there were not
sufficient Indonesian normal infections in our study to establish statistical significance
of that aspect. The V3 version of Zp therefore correlates more generally with NPC
incidence in our data set than the RMPS1 or EBER SNPs discussed above, perhaps
consistent with the EBV lytic cycle gene expression observed in NPC biopsy specimens
and high antibody titers to EBV lytic cycle antigens observed in NPC patients.
The LMP2A gene of EBV is also expressed in NPC, and a novel polymorphic region
in LMP2A was identified by examining phylogenetic trees of the N-terminal LMP2A
protein sequence encoded in its first exon (the part involved in signal transduction)
from 203 EBV strains in the MSA. The reference NC_007605 LMP2A protein sequence of
amino acids 63 to 82 (PYwgngdrhsdyqplgTqdQ) varies at the positions shown in
uppercase from the reference PYTQ (84 strains) to PYTP (32 strains), PDNP (48 strains),
and LDNP (39 strains). All of the NPC isolates are in the PYTQ and PYTP groups. The Y
of PYTP (Y64 of LMP2A) is not thought to be phosphorylated in LCLs, but the proline
amino acid changes are likely to have structural effects and are close in the protein
sequence to the functionally important PY1 motif (19), which is amino acids 56 to 60.
It would be interesting to examine functional effects of these sequence differences,
with the most variant form (LDNP) being found mainly in Hodgkin’s lymphoma and
PTLD samples of European origin in our data set.
Codon usage differs between latent and lytic cycle EBV genes. We have now
extended our previous analysis of positively selected amino acids (5) into a more
FIG 4 (A) Percentage of G55391A and EBER2 alleles in EBV sequences from NPC or normal samples from
China/Hong Kong and Indonesia. Details of strains are shown in Fig. S4, sheets 1 and 2. Significant
differences were determined with an ANOVA test. **, P  0.005. (B) Percentage of Zp P and V3 alleles in
EBV sequences from NPC or normal samples from Asia, Indonesia, White British (WB)/Australia, and
Kenya. Details of strains are shown in Fig. S4, sheet 3. Significant differences are indicated. **, P  0.005.
The Indonesian samples (NPC and normal samples) were collected in and around Jakarta and have been
described previously (35 and references therein).
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general comparison of codon usage of latent and lytic cycle EBV genes. In several
viruses, including, for example, human papillomaviruses (HPVs), variations in codon
usage have been linked to gene expression. Differences in codon usage in late HPV
genes compared to the early genes have been related to variations in tRNA pools
available for translation in the more differentiated layers of epithelium where late gene
expression occurs (20). We used the reference EBV NC_007605 (a chimera of U.S. and
African strains), Akata (Japanese), and AG876 (type 2) sequences for our analysis, and
Fig. 5 shows the combined results. The glycine/alanine repeat region of EBNA1 was
excluded to avoid it skewing the results for those codons. There are clear differences in
codon preference between the latent cycle genes of EBV and the lytic cycle genes.
Codon usage is more evenly spread in the latent cycle genes than the lytic cycle genes,
which show peaks of higher use of specific codons (Fig. 5).
In the representation of codon usage in Fig. 5, the values would all be 1 if all codons
were used equally. The statistical significance of the difference between latent and lytic
cycle genes shown in Fig. 5 was quantified by comparing the differences for each
codon to a value of 1 (data are shown in Fig. S5, sheet 3, strains combined). The
variation in codon usage was shown to be significantly greater in the lytic cycle genes than
in the latent cycle genes (P value of 0.0001 in an unpaired t test). Separation of the lytic
cycle genes into early and late groups showed no difference between these two groups
(Fig. 5), and each strain gave similar results when analyzed separately (Fig. S5).
Since latent persistence of EBV occurs in B lymphocytes but lytic replication may be
adapted to the suprabasal layers of stratified epithelium (21), it would be interesting to
determine whether the different codon usage patterns are related to differences in
tRNA populations in these cell types. Because the three strains analyzed (NC_007605,
Akata, and AG876) all derived from lymphoid infections, a similar analysis was done for
the GD2 EBV strain, directly sequenced from the epithelial cell infection in an NPC case.
The results (Fig. S5, sheet GD2) were very similar to those shown in Fig. 2 for the three
lymphoid isolates.
Heterogeneity of EBV isolates. Our previous PCR analysis of saliva for type 1 and
type 2 EBV (4) showed many examples of both types of EBV in single samples,
confirming that people can carry multiple strains of the virus. Sequence assembly
software is designed to produce a single unique assembled sequence where possible,
and this can make it difficult to recognize mixtures of sequences; mixtures may even
result in a failure to assemble de novo a complete sequence, even though there are
many sequence reads.
An example of a tendency of templated assembly to bias the result toward the
template sequence comes from our sequencing of the NKTLY97.1 NKT lymphoma cell
line (Table S1, omitted from the MSA of 241 sequences). Here, the BWA templated
assembly sequence was similar to the reference type 1 EBV (NC_007605), showing a
simple diagonal line on the dot matrix plot (Fig. 6A). The clustered signals from the
major internal repeat array and other repeats are visible, as expected (Fig. 6A). In
contrast, the de novo assembly dot matrix plot showed a section of the NKTLY97.1
genome around position 100,000 to be inverted, as well as some other differences (Fig.
6B). To ensure the inversion was not a sequence assembly error, PCR primers were
designed to span the predicted sequence at the right-hand end of the inversion. These
gave a clear product of the expected size with the NKTLY97.1 DNA but not with control
EBV DNA from the IB4 cell line or from a saliva sample, IMS 250 (Fig. 6C), confirming the
sequence inversion. The PCR product from the rearranged genome was sequenced,
confirming its identity and giving the breakpoint sequence as GGTTGGCGTAGCAGGA
GGCA/ACTGCTACGGGGGCG/CTCGTCTTCGCTCTTGGCC. The central ACTGCTACGGG
GGCG section of sequence inserted at the breakpoint did not align with EBV genome
on either side of the breakpoint. PCR of the equivalent region with primers for the
standard EBV genome gave a product with IB4 and the saliva sample but also a much
weaker signal from the NKTLY97.1 DNA. We conclude (Fig. 6C) that NKTLY97.1 contains
mostly the rearranged form of the EBV genome (which dominates in the de novo
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FIG 5 Relative synonymous codon usage for combined open reading frames of NC_007605, AG876, and Akata EBV.
(Upper) Latent and lytic cycle genes. (Lower) Lytic genes separated into early and late groups. Detailed values and results
for each strain analyzed separately are shown in Fig. S5.
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FIG 6 (A and B) Dot matrix plots of similarity between NKTLY97.1 and NC_007605 EBV sequences (window size, 30; minimum score,
85%; hash value, 8; MacVector). Templated BWA assembly of NKTLY97.1 (A) and de novo assembly of NKTLY97.1 (B) were used. (C)
(Continued on next page)
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assembly) but sufficient standard EBV genome to assemble into the standard form with
the templated assembly.
Eight of the EBV samples we sequenced and included in the MSA came from saliva
of chronic active EBV infection (CAEBV) patients from the United States (22). We
investigated the possibility that these samples also include some rearranged EBV
genomes similar to the het EBV that was found previously to be the basis of the chronic
lytic cycle activation in the P3HR1 cell line (23, 24). The het EBV is a rearranged defective
genome in which the latency Wp promoter is juxtaposed (WZhet) to the BZLF1 gene,
which induces the lytic cycle. The de novo assemblies of these CAEBV patient sequences
did not show rearranged EBV genomes, but typically not all of the contigs are used in
the final assembly. We therefore examined all other contigs that were obtained for
these samples for sequences from the start of the BZLF1 open reading to 500 nt
upstream, which would be characteristic of the het rearrangement (see Materials and
Methods for details). All of the contigs omitted from the final sequence assembly that
contained any part of this Zp sequence aligned to the standard EBV genome. The
contigs were also examined for Wp sequence between the TATA box to 300 nt
downstream, but again there were no such contigs that were not colinear with the
standard genome. Finally, for these samples we also examined the sequence reads that
had failed to map to their assembled genome. We searched these reads for ones that
either aligned to the WZhet junction or included any other junction between the start
of the BZLF1 open reading frame to 500 nt upstream and the Wp from the TATA box
to 300 nt downstream. Within these sequence positions we did not find any evidence
for a WZhet type of EBV genome rearrangement in the saliva of these CAEBV patients.
DISCUSSION
The purpose of this study was to create an expanded set of EBV genome sequences
sufficient to identify major patterns of variation that can, in future work, be investigated
functionally and tested for correlation with disease. Although many examples of EBV
from cell lines have been sequenced, most of the new sequences we report here come
from primary material, including saliva samples from healthy carriers, cancer samples,
and other diseases. EBV genomes from many different parts of the world are included
in this new data set, giving some insight into the degree of variation that may be
expected worldwide. This is the most comprehensive analysis of worldwide EBV
sequence variation reported so far.
Although the unique regions comprising most of the EBV genes have largely been
fully sequenced, the many repeat regions within the EBV genome remain a problem for
sequence assembly. The relatively short sequence reads obtained with Illumina se-
quencing generally make it difficult to allocate reads uniquely to any individual repeat,
although some progress has been made with the major internal repeat (25). Alternative
sequencing methods with much longer reads may be able to circumvent that limita-
tion, but they are not compatible with the enrichment protocols that were necessary to
allow the sequencing of EBV from primary infected cells described in this paper. Those
alternative methods are, however, useful for complete sequencing of EBV BAC clones
(26).
Another complication of Illumina sequencing EBV from primary material is the
presence of mixtures of strains. This was clearly illustrated in our analysis of the
NKTLY97.1 lymphoma and was also implied by the frequency of coinfection with type
1 and type 2 EBV in saliva samples collected from healthy students in our previous
study (4). Deconvoluting the sequence reads into multiple strains remains a compli-
cated matter, and mixed sequences may explain why some of the samples we analyzed
(see Table S1 in the supplemental material, MG298917-28) did not produce sufficiently
long contigs by de novo assembly to allow the EBV genome to be properly assembled,
FIG 6 Legend (Continued)
Agarose gel electrophoresis of products from PCR across the novel sequence boundary marked in panel B is shown with the 97.1
primers. PCR with WT primers (see Materials and Methods) is shown on the left.
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even though there were many sequence reads mapping to EBV. Those were primary
isolates from saliva or tonsils of healthy donors or saliva of chronic active EBV infection
patients.
Sequence heterogeneity of EBV during acute infectious mononucleosis has been
analyzed recently, showing that the heterogeneity reduced as the disease resolved to
a chronic infection (27). Eleven of the strains we sequenced were from Japanese
infectious mononucleosis patients (Table S1, 164 to 179 of the 241 aligned strains).
Those assembled sequences have some significant stretches of Ns in them, which can
arise from heterogeneity, and the European Nucleotide Archive (ENA) references for
those sequence reads are given in Table S1 to allow further investigation of that point.
In contrast, the EBV sequences from saliva of the majority of cases of chronic active
EBV infection patients assembled well, giving only standard EBV genome structures and
no evidence for the suspected WZhet type of rearranged genome. The sheared DNA
fragments that were enriched by the Sureselect method and sequenced were at least
500 bp in length, and the RNA oligonucleotides on the Sureselect beads were 120 nt
long. Therefore, wherever the breakpoint might occur in the DNA fragment there
would be at least 120 nt to anneal with a Sureselect oligonucleotide from either the Wp
or Zp side. Thus, we do not think that potential WZhet type rearranged DNA would
have been omitted from the enriched DNA that was sequenced. The results suggest
that these CAEBV cases are due to immunological or host genetic changes or other
failures in control of EBV rather than coinfection with a mutant EBV strain, similar to
WZhet EBV (22). It should be noted that in this study we only investigated the EBV
secreted in saliva from CAEBV cases and not the EBV present in cells in the blood or
other organs.
Principal-component analysis of SNP distribution clearly identifies the major type
1/type 2 distinction and clusters sequences from geographic regions. Our attempts to
relate variation in EBV genome regions to be characteristic of specific clusters of strains
were successful with the comparison of type 1 and type 2 but less clear with other
forms of geographic variation. Consistent with our earlier analysis of 84 EBV genomes,
the type 1/type 2 difference is mainly accounted for by variation in EBNA2 and the
EBNA3 locus, but the type 2 character of the EBNA3 region extends beyond the EBNA3
genes into the N terminus of gp350 on one side and through gp42 to Zp on the other
side. In view of the recent discovery that type 2 EBV also may be able to infect T cells
(28, 29), it will be important to test the effects of the variation in gp350 and gp42 in a
controlled system comparing type 1 and type 2 BAC EBV clones in which gp350 and
gp42 can be manipulated. The clear genetic linkage between EBNA2 and EBNA3, even
though the genes are 60 kb apart on the genetic map, also implies a currently unknown
mechanism that may relate to a functional compatibility between the proteins. Since
the positively selected amino acids in EBNA3 were not restricted to T cell epitopes (5),
it seems that the selection that links EBNA2 and EBNA3 is not due to immune
surveillance but due to functional compatibility. This could be investigated using BAC
EBV clones engineered to contain the different combinations of type 1 and type 2
EBNA2 and EBNA3.
The improved understanding of EBNA1 variation that has come from this analysis
will facilitate testing for effects on EBNA1 function. A recent study (30) addressed this
for two PSMVT C-terminal regions and found only modest effects but did not address
the major QCIGP variant or the linked variation in the N terminus of the protein. Our
results define the main forms of the EBNA1 protein that occur in normal and cancer
cells and will allow future studies to focus on the most prevalent EBNA1 sequences.
The differences in codon usage between latent and lytic cycle EBV genes demon-
strated here indicate evolution of the gene sequences to match tRNA populations in
the cells where these phases of EBV occur in the human body. Latent infection in
lymphocytes and lytic infection in epithelial cells would be one possibility for EBV. This
type of codon usage preference has not been reported yet for other herpesviruses,
partly because of the very few proteins expressed in the latent infections of most
herpesviruses.
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The extension of the PCA and SNP procedures to include insertions and deletions
made the analysis more susceptible to alignment weaknesses within the MSA but
increases our confidence that there are no other unrecognized regions of the EBV
genome yet to be discovered. We succeeded in identifying a previously unrecognized
insertion in some strains within the BART microRNA (miRNA) region. This insertion
might affect the processing of miRNAs, as even quite distant mutation of the BART
miRNA region has been found to affect miRNA levels (4). A more detailed investigation
of the SNPs that correspond to individual principle components of variation and the
geographic distribution will be published elsewhere. Although the PCA clearly sepa-
rated type 1 sequences from type 2, at least the first 3 components contributed to that
separation (Fig. 1A). There was not, for example, a simple correspondence between
PCA1 and EBNA3 variation and PCA2 and EBNA2 variation. It seems that the compo-
nents reflect complex overlapping sets of SNPs distributed along the genome. This
suggests some more fundamental selective pressures that operate on the evolution of
this viral genome, most likely combinations of multiple immunological and functional
selective mechanisms.
MATERIALS AND METHODS
EBV DNA sequencing and sequence assembly. Sample preparation, enrichment of EBV DNA, and
sequencing were as described previously (5), except sequencing was on the Illumina HiSeq 2500, with
paired-end reads of 250 nt generating fastq files. Reads were quality controlled using QUASR (5).
For initial BWA mapping (version 0.7.12) (31) to produce templated sequence assemblies, all reads
were mapped against NC_007605. Type 2 strains were also mapped against AG876 (NC_009334) to
generate consensus sequences. An alignment of these templated consensus sequences was used to
produce the phylogenetic tree shown in Fig. S1 in the supplemental material.
For de novo assembly, SPAdes assembler (version 3.5.0) (32) was used to generate files of contigs for
each sample. The SPAdes contigs were then run through scripts to improve the assembly by remapping
the ends of the contigs. The resulting contigs were filtered to use only those over 500 bp, and for each
sample the contigs from SPAdes were mapped using Geneious (www.geneious.com) against the
reference sequences NC_007605 and NC_009334 for type 2 strains. Contigs were also mapped to the
BWA consensus for that sample. These multiple-sequence alignments of contigs were then used to create
a consensus which was the de novo-assembled genome sequence.
Samples ebv6 to ebv15 were processed using CLC Genomics Workbench 7, including the CLC
Microbial Genome Finishing Module (Qiagen). EBV-specific reads, obtained by mapping against a
database of previously available EBV genomes, were de novo assembled into contigs and merged. Reads
were mapped back to the contigs and a consensus sequence extracted with a minimum depth threshold
of 20.
Samples ebv16 to ebv31, P(1-4)-T1, and the Japanese infectious mononucleosis samples (LS992259
to LS992269) were trimmed using TrimGalore (v0.3.7; Babraham Bioinformatics) with a quality threshold
of 20 and then aligned with BLASTN (U.S. National Library of Medicine) against database type 1 and 2
EBV genomes. The EBV-specific reads were de novo assembled using SPAdes v3.5.0 (32) into contigs.
Those with a length of 200 bp were used to generate a scaffold with an in-house R-script. Reads were
remapped against the scaffold with BBMap (Joint Genome Institute) and further processed with SAM-
tools, v.0.1.19 (Genome Research Ltd.), and Picard (Broad Institute). The consensus was extracted using
QUASR (Bioconductor) with a minimal depth threshold of 20 and a minimal base quality of 20.
Multiple EBV sequence alignment and PCA. The 138 new de novo-assembled EBV sequences and
published EBV sequences (241 in total) were aligned using MAFFT (33), with some manual editing to
reduce gapping in repeat sequence alignments. PCA was performed with custom Delphi/Pascal software
using a single-value decomposition library from SDL Component Suite (http://www.lohninger.com).
Details of the MSA and further analysis of geographic variation will be published separately.
Codon usage analysis. Genome sequences corresponding to annotated open reading frames in the
NC_007605 reference EBV sequence, AG876 (NC_009334), and Akata (KC207813) EBV were assembled
manually as fasta files. The Gly-Ala repeat of EBNA1 was omitted from the latent cycle protein sequences
used for this analysis to avoid bias. Relative synonymous codon usage was then determined using the
codon usage utility in the SMS programs (34) at http://www.bioinformatics.org/sms2/codon_usage.html.
Results were combined in Excel (Fig. S8) and plotted using GraphPad Prism (Fig. 5).
PCR of rearranged sequence in NKTLY97.1 DNA. Primers for the standard EBV genome were
GAAAATTCTTGAGCCGGC and ACATAATGGATGGGCAGG, and primers for the rearranged genome were
TACTGCGAAGGGAAGATG and ACATAATGGATGGGCAGG. PCR was 30 cycles with an annealing temper-
ature of 49°C.
CAEBV samples. Samples from patients with CAEBV were obtained from patients at the National
Institutes of Health who signed consent for a protocol that was approved by the Internal Research Board
of the National Institute of Allergy and Infectious Diseases. For analysis of EBV genomes in CAEBV cases,
contigs were searched on both strands for CAAAGATAGC, CAAGGTGCAATGTTT, ATCTCCCCTTTAAAG,
GGTTTGGGACGTGCTAAATTT, TAAAATAAGCTGGTGTCAAAAAT, TCAGGGGGGAGTCCAGATTC, and TATGG
CTGCTTCCTCCTTCTG. These were Zp sequences spread between the start of the BZLF1 open reading to
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500 nt upstream that were conserved in the MSA of this part of the genome. Contigs were also searched
on both strands for CCCCCTCCCTAGAA, TAAACGCGCTGGACTGAGAA, and GGTGAAGTCACAAACAAGCCC
from Wp, these sequences lying in the region between the TATA box to 300 nt downstream.
The sequence reads from the CAEBV cases were also remapped onto their corresponding consensus
sequence using the BWA mem aligner, and reads that did not map were then searched using the
sequences shown above, which would identify reads with translocations between Wp and Zp. Addition-
ally, reads that did not map were remapped against the WZhet sequence to check for alignments. Finally,
the CAEBV sequence reads were also mapped using a lower-stringency aligner (BWA aln) against the
NC_007605 reference sequence, and the reads that did not align were mapped on to the WZhet
sequences (M20820.1 and M33474.1).
Accession number(s). Sequences determined in the course of this work have been deposited in
GenBank, and their accession numbers are listed in Table S1.
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